News

Portfolio Companies
in the News

4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License

June 24, 2021

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

June 24, 2021

Antios Therapeutics’ ATI-2173 Demonstrates Potent Antiviral Activity and Evidence of Off-Treatment Sustained Viral Suppression in Chronic HBV Patients

June 23, 2021

Contego Medical, Inc. announced receipt of CE Mark approval for the Neuroguard IEP®

April 16, 2021

Impulse Dynamics Receives Approval to Sell Optimizer CCM Devices in China

February 22, 2021

Impulse Dynamics Announces FDA Approval for Magnetic Resonance Imaging

January 20, 2021

Impulse Dynamics Closes $60 Million Financing

January 12, 2021

Neuros Medical Announces Key Milestones in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain

January 7, 2021

Neuros Medical Raises $38.5M in Series BB Funding for Completion of Pivotal Clinical Study for Chronic Post-Amputation Pain

January 7, 2021

category

medtech

status

Current

headquarters

Plymouth, Minnesota

website

HistoSonics

HistoSonics has developed a system to destroy tumors completely non-invasively. Treatment is achieved using histotripsy, a novel form of energy that is safe, extremely precise, and able to be personalized for each patient. The initial indication is for treatment of liver tumors and the system is being studied in several other types of tumors.